Thrivent Financial For Lutherans increased its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 11.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 106,900 shares of the company’s stock after purchasing an additional 10,920 shares during the period. Thrivent Financial For Lutherans owned 0.28% of Aerie Pharmaceuticals worth $6,387,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Moody Aldrich Partners LLC purchased a new stake in shares of Aerie Pharmaceuticals in the 3rd quarter valued at about $1,046,000. Wells Fargo & Company MN raised its stake in Aerie Pharmaceuticals by 9.2% during the 3rd quarter. Wells Fargo & Company MN now owns 26,898 shares of the company’s stock valued at $1,308,000 after acquiring an additional 2,266 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Aerie Pharmaceuticals during the 4th quarter valued at approximately $617,000. Swiss National Bank raised its stake in Aerie Pharmaceuticals by 7.5% during the 3rd quarter. Swiss National Bank now owns 50,300 shares of the company’s stock valued at $2,445,000 after acquiring an additional 3,500 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Aerie Pharmaceuticals by 5.0% during the 3rd quarter. Rhumbline Advisers now owns 36,645 shares of the company’s stock valued at $1,781,000 after acquiring an additional 1,732 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.
AERI has been the subject of several analyst reports. Mizuho reaffirmed a “buy” rating and set a $87.00 price objective on shares of Aerie Pharmaceuticals in a research note on Tuesday, December 19th. Zacks Investment Research raised Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Canaccord Genuity set a $73.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 18th. BidaskClub downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, Cantor Fitzgerald set a $77.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 18th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $78.75.
Shares of AERI stock opened at $50.25 on Friday. The company has a market cap of $2,057.58, a PE ratio of -14.91 and a beta of 0.95. Aerie Pharmaceuticals Inc has a 12-month low of $38.14 and a 12-month high of $66.60. The company has a quick ratio of 10.09, a current ratio of 10.09 and a debt-to-equity ratio of 0.91.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, February 28th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.17). equities research analysts expect that Aerie Pharmaceuticals Inc will post -3.62 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Thrivent Financial For Lutherans Grows Position in Aerie Pharmaceuticals Inc (AERI)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/thrivent-financial-for-lutherans-raises-position-in-aerie-pharmaceuticals-inc-aeri.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.